Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2018 Nov 5

PMID 30392150

Citations 10

Authors

Adnan El-Achkar

Luis Souhami

Wassim Kassouf

Affiliations

Soon will be listed here.

Abstract

Purpose Of The Review: This review targets the latest literature on bladder preservation therapy with emphasis on trimodal therapy (TMT), highlighting its role in the management of muscle invasive bladder cancer (MIBC) and outlining future directions in bladder preservation research.

Recent Findings: TMT is the most promising bladder preservation treatment modality. Comparable results to contemporary radical cystectomy series are seen in properly selected patients. A multidisciplinary team approach is critical in the management of these patients. Future research is directed at the integration of immunotherapy into the treatment protocol. TMT, involving maximal transurethral resection followed by chemoradiation, is an attractive alternative to radical cystectomy with urinary diversion in carefully selected patients with muscle invasive disease. In the absence of randomized trial (RCT), comparison between TMT and cystectomy, based on retrospective data from large centers, suggests comparable oncological outcomes, with a favorable impact on quality of life.

Citing Articles

Development and validation of a novel nomogram model for predicting the survival of patients with T2-4a, N0-x, M0 bladder cancer: a retrospective cohort study.

Xia Y, Liu X, Ma B, Huang T, Xu D, Zhao C Am J Clin Exp Urol. 2023; 11(6):500-515.

PMID: 38148935 PMC: 10749381.

Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience.

Fallatah M, Alkahtani A, Alrumayyan M, Alotaibi M, Alkhateeb S, Mokhtar A Urol Ann. 2023; 15(4):406-411.

PMID: 38074180 PMC: 10699176. DOI: 10.4103/ua.ua_50_23.

Differentiation of bladder cancer stages using the vesical imaging -reporting and data system and apparent diffusion coefficient.

Liu W, Chen R, Liu X, Zhou B, Shen Y, Zhou L Quant Imaging Med Surg. 2023; 13(8):4897-4907.

PMID: 37581052 PMC: 10423393. DOI: 10.21037/qims-22-1184.

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.

de Ruiter B, van de Kamp M, van Steenbergen J, Franckena M, Boormans J, de Feijter J Eur Urol Open Sci. 2022; 39:7-13.

PMID: 35528785 PMC: 9068732. DOI: 10.1016/j.euros.2022.02.010.

Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis.

Kool R, Yanev I, Hijal T, Vanhuyse M, Cury F, Souhami L Can Urol Assoc J. 2022; 16(6):189-198.

PMID: 35099381 PMC: 9245963. DOI: 10.5489/cuaj.7430.

References

Krasnow R, Drumm M, Roberts H, Niemierko A, Wu C, Wu S . Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017; 72(1):54-60. DOI: 10.1016/j.eururo.2016.12.002. View

Seisen T, Sun M, Lipsitz S, Abdollah F, Leow J, Menon M . Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017; 72(4):483-487. DOI: 10.1016/j.eururo.2017.03.038. View

Tanabe K, Yoshida S, Koga F, Inoue M, Kobayashi S, Ishioka J . High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. Clin Genitourin Cancer. 2015; 13(4):e243-e251. DOI: 10.1016/j.clgc.2015.03.002. View

Mak R, Hunt D, Shipley W, Efstathiou J, Tester W, Hagan M . Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014; 32(34):3801-9. PMC: 4239302. DOI: 10.1200/JCO.2014.57.5548. View

Huddart R, Hall E, Hussain S, Jenkins P, Rawlings C, Tremlett J . Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013; 87(2):261-9. PMC: 3753507. DOI: 10.1016/j.ijrobp.2013.06.2044. View

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

Hussain M, Glass T, Forman J, Sakr W, Smith D, Al-Sarraf M . Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol. 2000; 165(1):56-60; discussion 60-1. DOI: 10.1097/00005392-200101000-00014. View

Tunio M, Hashmi A, Qayyum A, Mohsin R, Zaeem A . Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2011; 82(3):e457-62. DOI: 10.1016/j.ijrobp.2011.05.051. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

10.

Withers H, Taylor J, Maciejewski B . The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988; 27(2):131-46. DOI: 10.3109/02841868809090333. View

11.

Kulkarni G, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P . Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017; 35(20):2299-2305. DOI: 10.1200/JCO.2016.69.2327. View

12.

Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N . Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011; 41(12):1373-9. DOI: 10.1093/jjco/hyr150. View

13.

James N, Hussain S, Hall E, Jenkins P, Tremlett J, Rawlings C . Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366(16):1477-88. DOI: 10.1056/NEJMoa1106106. View

14.

Choudhury A, West C, Porta N, Hall E, Denley H, Hendron C . The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). Br J Cancer. 2017; 116(5):649-657. PMC: 5344298. DOI: 10.1038/bjc.2017.2. View

15.

El-Achkar A, Kassouf W . Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Eur Urol. 2018; 73(5):810-811. DOI: 10.1016/j.eururo.2018.01.034. View

16.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

17.

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

18.

Efstathiou J, Bae K, Shipley W, Kaufman D, Hagan M, Heney N . Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009; 27(25):4055-61. PMC: 2734419. DOI: 10.1200/JCO.2008.19.5776. View

19.

Shrivastava S, Mansure J, Almajed W, Cury F, Ferbeyre G, Popovic M . The Role of HMGB1 in Radioresistance of Bladder Cancer. Mol Cancer Ther. 2016; 15(3):471-9. DOI: 10.1158/1535-7163.MCT-15-0581. View

20.

Hoskin P, Sibtain A, Daley F, Wilson G . GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003; 89(7):1290-7. PMC: 2394309. DOI: 10.1038/sj.bjc.6601260. View